Acknowledgements
neuroblastoma, Cancer
ONCOLOGY, SUTTON, NEUROBLASTOMA, CANCER
Recloning and production of the ch14.18 monoclonal antibody was done at Polymun, Vienna, Austria, and was enabled by a SIOPEN fundraising effort in 2001. Apeiron Biologics provided the product during the study. Neither Polymun nor Apeiron Biologics had a role in the study design or the analysis. Apeiron Biologics and later EUSA Pharma (liscensee of the product as of 2017) provided funding for the clinical research organization FGK Clinical Research GmbH and Gabriele Dürr-Watzka and her team who supported with the conduct of the study, data collection and analysis. Further support for sample analysis was obtained from Hector Stiftungen (Grant M2116). The authors express their gratitude and appreciation to the treating physicians, academic clinical research and care teams, and, most importantly, the patients and families facing high-risk neuroblastoma for their committed participation in the study. The authors thank Sandra Riesebeck, Maria Asmus, Manuela Brüser, and Theodor Koepp (University Medicine Greifswald, Pediatric Hematology and Oncology, Greifswald, Germany) and Dasa Janousek, Ingrid Pribill, and Claudia Zeiner-Koglin (St. Anna Kinderkrebsforschung e.V., Children’s Cancer Research Institute, Vienna, Austria) for excellent assistance. Editorial assistance for the development of the manuscript was provided by Clare Ryles and Katrin Male of mXm Medical Communications funded by EUSA Pharma. Editorial advice was also provided by Prof Andy Pearson from the Institute of Cancer Research at the Royal Marsden Hospital, Sutton, UK. The content of the article represents the views of the authors and has not been influenced by third-party sponsorship.